​

Arcus Biosciences (RCUS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RCUS Stock Forecast

Arcus Biosciences (RCUS) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $33.00, with a high of $46.00 and a low of $20.00. This represents a 318.78% increase from the last price of $7.88.

$5 $14 $23 $32 $41 $50 High: $46 Avg: $33 Low: $20 Last Closed Price: $7.88

RCUS Stock Rating

Arcus Biosciences stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (87.50%), 2 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 2 14 Strong Sell Sell Hold Buy Strong Buy

RCUS Price Target Upside V Benchmarks

TypeNameUpside
StockArcus Biosciences318.78%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--8
Avg Price Target--$32.13
Last Closing Price$7.88$7.88$7.88
Upside/Downside--307.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25382--13
Mar, 25382--13
Feb, 25283--13
Jan, 25283--13
Dec, 24283--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024Yigal NochomovitzCitigroup$46.00$17.42164.06%483.76%
Oct 21, 2024Emily BodnarH.C. Wainwright$20.00$18.448.46%153.81%
Oct 08, 2024Judah FrommerMorgan Stanley$35.00$18.0893.58%344.16%
Oct 08, 2024Eva Fortea VerdejoWells Fargo$29.00$18.0860.40%268.02%
Aug 09, 2024Jason ZemanskyBank of America Securities$23.00$13.6968.01%191.88%
Jul 08, 2024Peter LawsonBarclays$25.00$14.0078.57%217.26%
Jun 24, 2024Asthika GoonewardeneTruist Financial$44.00$16.45167.48%458.38%
Jun 04, 2024Peter LawsonBarclays$35.00$16.15116.72%344.16%
Dec 20, 2022Citigroup$42.00$20.66103.29%432.99%
Nov 23, 2022Citigroup$37.00$27.0037.04%369.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024CitigroupBuyBuyhold
Oct 21, 2024Wells FargoNeutralNeutralhold
Oct 21, 2024H.C. WainwrightNeutralinitialise
Oct 08, 2024Morgan StanleyUnderperformOverweightinitialise
Oct 08, 2024Wells FargoOverweightinitialise
Oct 03, 2024WedbushNeutralNeutralhold
Aug 09, 2024Bank of America SecuritiesNeutralNeutralhold
Jul 08, 2024WedbushBuyBuyhold
Jul 08, 2024BarclaysOverweightOverweighthold
Jul 05, 2024Cantor FitzgeraldOverweightOverweighthold

Financial Forecast

EPS Forecast

$-9 $-7 $-5 $-3 $-1 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.13$0.76$-3.71$-4.15$-3.14----
Avg Forecast$-2.18$-4.35$-3.88$-4.00$-3.41$-4.33$-4.39$-4.67$-1.29
High Forecast$-1.24$-2.48$-1.30$-3.89$-2.61$-3.13$-1.95$-2.65$0.11
Low Forecast$-3.89$-7.76$-8.27$-4.18$-4.16$-5.95$-6.57$-7.29$-3.73
Surprise %-2.29%-117.47%-4.38%3.75%-7.92%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$77.52M$382.88M$112.00M$117.00M$258.00M----
Avg Forecast$75.97M$40.33M$102.64M$113.67M$246.83M$224.94M$244.84M$260.13M$635.46M
High Forecast$121.83M$64.67M$191.93M$119.63M$256.90M$484.46M$247.16M$270.13M$1.57B
Low Forecast$50.88M$27.01M$50.13M$109.48M$233.02M$46.21M$242.52M$250.13M$105.36M
Surprise %2.04%849.43%9.12%2.93%4.53%----

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-116.68M$53.00M$-267.00M$-307.00M$-283.00M----
Avg Forecast$-92.57M$1.59B$1.43B$-307.00M$-270.00M$-385.92M$-416.98M$-429.11M$-95.16M
High Forecast$-73.14M$1.98B$1.80B$-221.65M$-193.25M$-231.63M$-144.22M$-195.92M$8.04M
Low Forecast$-112.01M$1.20B$1.05B$-392.35M$-307.63M$-440.36M$-485.96M$-539.65M$-276.34M
Surprise %26.04%-96.66%-118.73%-4.81%----

RCUS Forecast FAQ

Is Arcus Biosciences stock a buy?

Arcus Biosciences stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arcus Biosciences is a favorable investment for most analysts.

What is Arcus Biosciences's price target?

Arcus Biosciences's price target, set by 16 Wall Street analysts, averages $33 over the next 12 months. The price target range spans from $20 at the low end to $46 at the high end, suggesting a potential 318.78% change from the previous closing price of $7.88.

How does Arcus Biosciences stock forecast compare to its benchmarks?

Arcus Biosciences's stock forecast shows a 318.78% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Arcus Biosciences over the past three months?

  • April 2025: 23.08% Strong Buy, 61.54% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 23.08% Strong Buy, 61.54% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 15.38% Strong Buy, 61.54% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.

What is Arcus Biosciences’s EPS forecast?

Arcus Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.33, marking a 37.90% increase from the reported $-3.14 in 2024. Estimates for the following years are $-4.39 in 2026, $-4.67 in 2027, and $-1.29 in 2028.

What is Arcus Biosciences’s revenue forecast?

Arcus Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $224.94M, reflecting a -12.81% decrease from the reported $258M in 2024. The forecast for 2026 is $244.84M, followed by $260.13M for 2027, and $635.46M for 2028.

What is Arcus Biosciences’s net income forecast?

Arcus Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-386M, representing an 36.37% increase from the reported $-283M in 2024. Projections indicate $-417M in 2026, $-429M in 2027, and $-95.164M in 2028.